m1A/m5C/m6A/m7G调控基因预测胃癌预后及免疫关联性

被引:0
|
作者
陈小梅 [1 ,2 ]
王安奇 [1 ,2 ]
杨积祯 [3 ]
于淼 [1 ]
机构
[1] 甘肃省人民医院国家胃肠肿瘤诊治重点实验室
[2] 甘肃省人民医院临床研究与转化医学研究所
[3] 不详
关键词
m1A; m5C; m6A; m7G; 胃癌; 预后; 免疫浸润;
D O I
暂无
中图分类号
R735.2 [胃肿瘤];
学科分类号
摘要
目的 基于m1A/m5C/m6A/m7G甲基化调控基因建立胃癌预后风险预测模型,并分析该模型与免疫的关联性。方法 通过癌症基因组图谱(TCGA)-胃癌数据集筛选表达具有显著差异的m1A/m5C/m6A/m7G调控基因,通过单基因Cox回归分析和LASSO算法构建预后风险评分(risk score, RS)模型,使用Kaplan-Meier(K-M)统计进行RS模型验证,并应用细胞系进行RT-qPCR验证。利用单因素、多因素Cox回归分析建立nomogram模型。使用CIBERSORT算法和estimate包进行免疫关联性分析。结果 建立了基于八个甲基化调控基因的预后RS模型,将胃癌患者分为高风险和低风险。这八个基因在胃癌细胞系中高表达(P <0.05)。在TCGA-胃癌训练集和GSE62254-验证集中,患者总生存率(OS)与分组状态之间存在显著相关性(P <0.001)。nomogram生存模型预测的1年(C-index=0.703)、3年(C-index=0.729)和5年(C-index=0.734)生存率与实际生存率的一致性较好。免疫关联性分析表明,与低风险患者组相比,高风险患者组免疫评分和免疫检查点相关基因的表达较高(P <0.05)。结论 基于m1A/m5C/m6A/m7G调控基因的预后RS模型可预测胃癌预后并指导个体免疫治疗决策。
引用
收藏
页码:1230 / 1237
页数:8
相关论文
共 27 条
  • [1] Targeting TFH cells in human diseases and vaccination: rationale and practice[J] Yu Di;Walker Lucy S. K.;Liu Zheng;Linterman Michelle A.;Li Zhanguo Nature Immunology 2022,
  • [2] Regulatory function of DNA methylation mediated lncRNAs in gastric cancer[J] Li Nan;Zeng Anqi;Wang Qian;Chen Maohua;Zhu Shaomi;Song Linjiang Cancer Cell International 2022,
  • [3] Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.[J] Xu Liangliang;Zou Chang;Zhang Shanshan;Chu Timothy Shun Man;Zhang Yan;Chen Weiwei;Zhao Caining;Yang Li;Xu Zhiyuan;Dong Shaowei;Yu Hao;Li Bo;Guan Xinyuan;Hou Yuzhu;Kong FengMing Journal of hematology & oncology 2022,
  • [4] Construction and Validation of a m7G-Related Gene-Based Prognostic Model for Gastric Cancer&#13;[J] Li Xin yu;Wang Shou lian;Chen De hu;Liu Hui;You Jian Xiong;Su Li xin;Yang Xi tao Frontiers in Oncology 2022,
  • [5] The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma&#13;[J] Li Dan;Li Kai;Zhang Wei;Yang Kong Wu;Mu De An;Jiang Guo Jun;Shi Rong Shu;Ke Di Frontiers in Immunology 2022,
  • [6] N<sup>7</sup>-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis.[J] Han Hui;Yang Chunlong;Ma Jieyi;Zhang Shuishen;Zheng Siyi;Ling Rongsong;Sun Kaiyu;Guo Siyao;Huang Boxuan;Liang Yu;Wang Lu;Chen Shuang;Wang Zhaoyu;Wei Wei;Huang Ying;Peng Hao;Jiang YiZhou;Choe Junho;Lin Shuibin Nature communications 2022,
  • [7] RBM15 promotes hepatocellular carcinoma progression by regulating N6-methyladenosine modification of YES1 mRNA in an IGF2BP1-dependent manner[J] Cai Xianlei;Chen Yunhao;Man Da;Yang Beng;Feng Xiaode;Zhang Deguo;Chen Junru;Wu Jian Cell Death Discovery 2021,
  • [8] Clinical correlations and prognostic value of Nudix hydroxylase 10 in patients with gastric cancer.[J] Chen Diqun;Zhang Rouxin;Xie Aosi;Yuan Jinpeng;Zhang Jinhai;Huang Yongjian;Zhang Hongxia;Zhang Feiran Bioengineered 2021,
  • [9] RNA methylation and cancer treatment.[J] Yang Baochen;Wang JingQuan;Tan Yao;Yuan Runzhu;Chen ZheSheng;Zou Chang Pharmacological research 2021,
  • [10] miR-4293 upregulates lncRNA WFDC21P by suppressing mRNA-decapping enzyme 2 to promote lung carcinoma proliferation.[J] Zhang Qian;Yan YunFei;Lv Qing;Li YouJie;Wang RanRan;Sun GuangBin;Pan Li;Hu JinXia;Xie Ning;Zhang Can;Tian BaoCheng;Jiao Fei;Xu Sen;Wang PingYu;Xie ShuYang Cell death & disease 2021,